Citations

Clear

6273 citation(s) found for "To, Andrew".

RNA Sequencing Identifies Transcriptionally Viable Gene Fusions in Esophageal Adenocarcinomas
Blum, Andrew E., Venkitachalam, Srividya , Kieber-Emmons, Ann Marie, Ravi, Lakshmeswari, Chandar, Apoorva K., Iyer, Prasad G. , Wang, Jean S. , Shaheen, Nicholas J. , Barnholtz‐Sloan, Jill S. , Markowitz, Sanford D. , Willis, Joseph , Shyr, Yu , Chak, Amitabh , Varadan, Vinay , Guda, Kishore , Guo, Yan Ping , Canto, Marcia Irene , Willis, Joseph E , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Research | August 8, 2016 | Volume: 76 | Issue: 19 | Pages: 5628-5633

10.1158/0008-5472.can-16-0979 | PMID 27503924 Get It

Abstract Esophageal adenocarcinoma is a deadly cancer with increasing incidence in the United States, but mechanisms underlying pathogenesis are still mostly elusive. In addressing this question, we assessed gene fusion landscapes by comprehensive RNA sequencing (RNAseq) of 55 pretreatment esophageal adenocarcinoma and 49 nonmalignant biopsy tissues from patients undergoing endoscopy for Barrett's esophagus. In this cohort, we identified 21 novel candidate esophageal adenocarcinoma–associated fusions occurring in 3.33% to 11.67% of esophageal adenocarcinomas. Two candidate fusions were selected for validation by PCR and Sanger sequencing in an independent set of pretreatment esophageal adenocarcinoma (N = 115) and nonmalignant (N = 183) biopsy tissues. In particular, we observed RPS6KB1–VMP1 gene fusion as a recurrent event occurring in approximately 10% of esophageal adenocarcinoma cases. Notably, esophageal adenocarcinoma cases harboring RPS6KB1–VMP1 fusions exhibited significantly poorer overall survival as compared with fusion-negative cases. Mechanistic investigations established that the RPS6KB1–VMP1 transcript coded for a fusion protein, which significantly enhanced the growth rate of nondysplastic Barrett's esophagus cells. Compared with the wild-type VMP1 protein, which mediates normal cellular autophagy, RPS6KB1–VMP1 fusion exhibited aberrant subcellular localization and was relatively ineffective in triggering autophagy. Overall, our findings identified RPS6KB1–VMP1 as a genetic fusion that promotes esophageal adenocarcinoma by modulating autophagy-related processes, offering new insights into the molecular pathogenesis of esophageal adenocarcinomas. Cancer Res; 76(19); 5628–33. ©2016 AACR.
Arguing against the proposed definition changes of PD
Duda, John E., Ferman, Tanis J. , Goldman, Jennifer G. , Growdon, John H., Hurtig, Howard I., Kaufer, Daniel , Kantarci, Kejal , Leverenz, James B. , Lippa, Carol F. , McKeith, Ian G. , Singleton, Andrew , Taylor, Angela , Tsuang, Debby W. , Zabetian, Cyrus P. , Boeve, Bradley F. , Dickson, Dennis W. , Galasko, Douglas , Galvin, James E. , López, Oscar L. , Weintraub, Daniel , Goldman, Jennifer G , Leverenz, James B , Kantarci, Kejal , Zabetian, Cyrus P , Ferman, Tanis J

Mayo Clinic

Movement Disorders | August 5, 2016 | Volume: 31 | Issue: 11 | Pages: 1619-1622

10.1002/mds.26721 | PMID 27492190 Get It

ABSTRACT As members of the Lewy Body Dementia Association Scientific Advisory Council, we aim to address some of the issues raised in the article titled “Time to Redefine PD? Introductory Statement of the MDS Task Force on the Definition of Parkinson's Disease.” In particular, we suggest that the 1‐year rule distinguishing Parkinson's disease dementia from dementia with Lewy bodies is worth maintaining because it serves an important purpose in clinical practice and clinical and basic science research and when helping the lay community understand the complexity of these different clinical phenotypes. Furthermore, we believe that adding an additional diagnostic label, “PD (dementia with Lewy bodies subtype),” will confuse rather than clarify the distinction between dementia with Lewy bodies and PD or PD dementia, and will not improve management or expedite therapeutic development. We present arguments supporting our contentions. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
A recurring mutation in the respiratory complex 1 protein NDUFB11 is responsible for a novel form of X-linked sideroblastic anemia
Lichtenstein, Daniel A. , Crispin, Andrew, Sendamarai, Anoop K. , Campagna, Dean R. , Schmitz‐Abe, Klaus , Sousa, Cristovão M. , Kafina, Martin D. , Schmidt, Paul J. , May, Alison, Patnaik, Mrinal M. , Kimmelman, Alec C. , Bottomley, Sylvia S. , Markianos, Kyriacos , Fleming, Mark D. , Niemeyer, Charlotte Marie , Porter, John B. , Heeney, Matthew M. , Paw, Barry H. , Lichtenstein, Dan

Mayo Clinic

Blood | August 4, 2016 | Volume: 128 | Issue: 15 | Pages: 1913-1917

10.1182/blood-2016-05-719062 | PMID 27488349 Get It

Key Points A recurring mutation in NDUFB11 causes congenital sideroblastic anemia. The NDUFB11 p.93del mutation impairs erythroid proliferation, but not differentiation.
What Is the Correct Approach for Comparing GFR by Different Methods across Levels of GFR?
Kremers, Walter K. , Rule, Andrew D. , Kremers, Walter K

Mayo Clinic

Clinical Journal of the American Society of Nephrology | August 3, 2016 | Volume: 11 | Issue: 9 | Pages: 1518-1521

10.2215/cjn.07530716 | PMID 27489300 Get It

Profibrotic up‐regulation of glucose transporter 1 by TGF‐β involves activation of MEK and mammalian target of rapamycin complex 2 pathways
Andrianifahanana, Mahefatiana, Hernandez, Danielle M. , Yin, Xueqian , Kang, Jeong Han , Yi, Eunhee S. , Roden, Anja C. , Leof, Edward B. , Jung, Mi-Yeon, Wang, Youli, Jung, Miyeon , Wang, Youli , Limper, Andrew H.

Mayo Clinic

The FASEB Journal | August 1, 2016 | Volume: 30 | Issue: 11 | Pages: 3733-3744

10.1096/fj.201600428r | PMID 27480571 Get It

ABSTRACT TGF‐β plays a central role in the pathogenesis of fibroproliferative disorders. Defining the exact underlying molecular basis is therefore critical for the development of viable therapeutic strategies. Here, we show that expression of the facilitative glucose transporter 1 (GLUT1) is induced by TGF‐β in fibroblast lines and primary cells and is required for the profibrotic effects of TGF‐β. In addition, enhanced GLUT1 expression is observed in fibrotic areas of lungs of both patients with idiopathic pulmonary fibrosis and mice that are subjected to a fibrosis‐inducing bleomycin treatment. By using pharmacologic and genetic approaches, we demonstrate that up‐regulation of GLUT1 occurs via the canonical Smad2/3 pathway and requires autocrine activation of the receptor tyrosine kinases, platelet‐derived and epidermal growth factor receptors. Engagement of the common downstream effector PI3K subsequently triggers activation of the MEK and mammalian target of rapamycin complex 2, which cooperate in regulating GLUT1 expression. Of note, inhibition of GLUT1 activity and/or expression is shown to impair TGFβ–driven fibrogenic processes, including cell proliferation and production of profibrotic mediators. These findings provide new perspectives on the interrelation of metabolism and profibrotic TGF‐β signaling and present opportunities for potential therapeutic intervention.—Andrianifahanana, M., Hernandez, D. M., Yin, X., Kang, J.‐H., Jung, M.‐Y., Wang, Y., Yi, E. S., Roden, A. C., Limper, A. H., Leof, E. B. Profibrotic up‐regulation of glucose transporter 1 by TGF‐β involves activation of MEK and mammalian target of rapamycin complex 2 pathways. FASEB J. 30, 3733–3744 (2016) www.fasebj.org
Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration
Group, AOCS Study, Reid, Brett M. , Earp, Madalene A. , Chen, Y. Ann , Monteiro, Álvaro N.A. , Chen, Zhihua , Chenevix‐Trench, Georgia , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vanderstichele, Adriaan , Niewenhuyse, Els Van, Vergote, Ignace , Rossing, Mary Anne, Chang‐Claude, Jenny, Moysich, Kirsten, Odunsi, Kunle , Goodman, Marc T. , Shvetsov, Yurii B. , Thompson, Pamela J., Dörk, Thilo , Bogdanova, Natalia , Pelttari, Liisa M. , Leminen, Arto, Edwards, Robert P., Ness, Roberta B., Kelley, Joseph L., Lester, Jenny, Jensen, Allan , Hildebrandt, Michelle, Liang, Dong , Lu, Karen H., Wu, Xifeng , Levine, Douglas A. , Bisogna, Maria, Berchuck, Andrew, Terry, Kathryn L. , Tworoger, Shelley S. , Cunningham, Julie M. , Winham, Stacey J. , Olson, Sara H. , Kiemeney, Lambertus A. , Massuger, Leon F.A.G. , Moffitt, Melissa , Le, Nhu, Kelemen, Linda E. , Lubiński, Jan , Wentzensen, Nicolas, Brinton, Louise A. , Lissowska, Jolanta , Yang, Hanna , Høgdall, Estrid , Høgdall, Claus , Lundvall, Lene, Song, Honglin , Campbell, Ian , Eccles, Diana , McNeish, Iain A. , Whittemore, Alice S. , McGuire, Valerie, Sieh, Weiva , Rothstein, Joseph H. , Phelan, Catherine M., Narod, Steven A., McLaughlin, John, Ziogas, Argyrios, Menon, Usha , Gayther, Simon A. , Ramus, Susan J. , Pearce, Celeste Leigh, Wu, Anna H. , Kupryjańczyk, Jolanta , Dansonka‐Mieszkowska, Agnieszka , Schildkraut, Joellen M. , Cheng, Jin Q. , Goode, Ellen L. , Sellers, Thomas A. , Lu, Karen H. , Lambrechts, Diether , Earp, Madalene, Cunningham, Julie, Permuth, Jennifer B. , Group, AOCS Study, Doherty, Jennifer A. , Wilkens, Lynne R. , Bützow, Ralf C. , Nevanlinna, Heli , Modugno, Francesmary , Heitz, Florian , Karlan, Beth Y. , Lester, Jenny, Kjær, Susanne K. , Giles, Graham G. , Cramer, Daniel W. , Poole, Elizabeth M. , Bandera, Elisa V. , Fridley, Brooke L. , Orlow, Irene , Bjørge, Line , Pejovic, Tanja B. , Cook, Linda S. , Brooks‐Wilson, Angela , Gronwald, Jacek , Wentzensen, Nicolas , Pharoah, Paul D.P. , Risch, Harvey A. , McLaughlin, John, Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra , Pelttari, L M , Winham, Stacey J , Dörk, Thilo , Lambrechts, Diether , Kiemeney, Lambertus A , McNeish, Iain A , Ramus, Susan J , Tworoger, Shelley S , Vanderstichele, Adriaan , Jensen, Allan , Eccles, Diana , Menon, Usha , Monteiro, Alvaro N , Moysich, Kirsten , Lissowska, Jolanta , Campbell, Ian G , Kupryjanczyk, Jolanta , Lambrechts, Diether , Sieh, Weiva , Bogdanova, Natalia V , Chenevix-Trench, Georgia , Høgdall, Estrid , Høgdall, Claus K , Lubinski, Jan , Goodman, Marc T

Mayo Clinic

Oncotarget | July 28, 2016 | Volume: 7 | Issue: 45 | Pages: 72381-72394

10.18632/oncotarget.10546 | PMID 27911851 Get It

Early event status informs subsequent outcome in newly diagnosed follicular lymphoma
Bachy, Emmanuel , Ghesquières, Hervé , Ansell, Stephen M. , Nowakowski, Grzegorz S. , Thompson, Carrie A. , Inwards, David J. , Allmer, Cristine, Chassagne‐Clément, Catherine, Nicolas‐Virelizier, Emmanuelle , Sebban, Catherine, Lebras, Laure , Macon, William R. , Feldman, Andrew L. , Syrbu, Sergei , Traverse‐Glehan, Alexandra, Coiffier, Bertrand , Weiner, George J. , Salles, Gilles , Link, Brian K. , Maurer, Matthew J. , Sarkozy, Clémentine , Slager, Susan L. , Witzig, Thomas E. , Habermann, Thomas M. , Cerhan, James R. , Feldman, Andrew L , Link, Brian K , Salles, Gilles A , Weiner, George , Bachy, Emmanuel , Syrbu, Sergei

Mayo Clinic

American Journal of Hematology | July 28, 2016 | Volume: 91 | Issue: 11 | Pages: 1096-1101

10.1002/ajh.24492 | PMID 27465588 Get It

Recent advances in follicular lymphoma (FL) have resulted in prolongation of overall survival (OS). Here we assessed if early events as defined by event‐free survival (EFS) at 12 and 24 months from diagnosis (EFS12/EFS24) can inform subsequent OS in FL. 920 newly diagnosed grade 1‐3A FL patients enrolled on the University of Iowa/Mayo Clinic Lymphoma SPORE Molecular Epidemiology Resource (MER) from 2002‐2012 were initially evaluated. EFS was defined as time from diagnosis to progression, relapse, re‐treatment, or death due to any cause. OS was compared to age‐and‐sex‐matched survival in the general US population using standardized mortality ratios (SMR) and 95% confidence intervals (CI). We used a cohort of 412 FL patients from two Lyon, France hospital registries for independent replication. Patients who failed to achieve EFS12 had poor subsequent OS (MER SMR = 3.72, 95%CI: 2.78‐4.88; Lyon SMR = 8.74, 95%CI: 5.41‐13.36). Conversely, patients achieving EFS12 had no added mortality beyond the background population (MER SMR = 0.73, 95%CI: 0.56‐0.94, Lyon SMR = 1.02, 95%CI: 0.58‐1.65). Patients with early events after immunochemotherapy had especially poor outcomes (EFS12 failure: MER SMR = 17.63, 95%CI:11.97‐25.02, Lyon SMR = 19.10, 95%CI:9.86‐33.36; EFS24 failure: MER SMR = 13.02, 95%CI:9.31‐17.74, Lyon SMR = 7.22, 95%CI:4.13‐11.74). In a combined dataset of all patients from both cohorts, baseline FLIPI was no longer informative in EFS12 achievers. Reassessment of patient status at 12 months from diagnosis in follicular lymphoma patients, or at 24 months in patients treated with immunochemotherapy, is a strong predictor of subsequent overall survival in FL. Early event status provides a simple, clinically relevant endpoint for studies assessing outcome in FL. Am. J. Hematol. 91:1096–1101, 2016. © 2016 Wiley Periodicals, Inc.
Telomere structure and maintenance gene variants and risk of five cancer types
Karami, Sara , Pierce, Brandon L. , Nutter, Ellen L., Schumacher, Fredrick R. , Lindström, Sara , Witte, John S. , Fang, Shenying , Han, Jiali , Kraft, Peter , Song, Fengju , Hung, Rayjean J., McKay, James , Gruber, Stephen B. , Risch, Angela , Shen, Hongbing , Haiman, Christopher A. , Boardman, Lisa, Casey, Graham , Peters, Ulrike , Olama, Ali Amin Al , Berndt, Sonja I. , Brennan, Paul , Brenner, Hermann , Brinton, Louise A. , Caporaso, Neil E. , Chang‐Claude, Jenny , Cunningham, Julie M. , Easton, Douglas F. , Eeles, Rosalind A. , Eisen, Timothy, Gala, Manish , Gallinger, Steven , Gayther, Simon A. , Goode, Ellen L. , Grönberg, Henrik , Henderson, Brian E., Houlston, Richard S. , Joshi, Amit D. , Küry, Sébastien , Landi, Mari T., Muir, Kenneth , Permuth‐Wey, Jenny, Phelan, Catherine, Ramus, Susan J. , Schildkraut, Joellen M. , Slattery, Martha L. , Song, Honglin , Wentzensen, Nicolas , Zanke, Brent W., Sellers, Thomas A. , Zheng, Wei , Chatterjee, Nilanjan , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Hung, Rayjean J. , Han, Younghun , Pande, Mala , Cheng, Iona C. , Rudd, James , Kote‐Jarai, Zsofia , Hunter, David J. , Hung, Rayjean J., Chanock, Stephen Jacob , Boardman, Lisa, Ulrich, Cornelia M. , Berchuck, Andrew , Bezieau, Stéphane , Chan, Andrew T. , Christiani, David C. , Marchand, Loı̈c Le , Newcomb, Polly A. , Pharoah, Paul D.P. , Potter, John D. , Risch, Harvey A. , White, Emily E. , Wiklund, Fredrik E. , Amos, Christopher I. , Doherty, Jennifer A. , TRICL, on behalf of GECCO and the GAME‐ON Network: CORECT, DRIVE, ELLIPSE, FOCI, and, Ramus, Susan J , Houlston, Richard S , Eeles, Rosalind A , Hung, Rayjean J , Muir, Kenneth , Kury, Sebastien , Brenner, Hermann , Han, Jiali , Kraft, Peter , Zheng, Wei , Risch, Angela , Shen, Hongbing

Mayo Clinic

International Journal of Cancer | July 26, 2016 | Volume: 139 | Issue: 12 | Pages: 2655-2670

10.1002/ijc.30288 | PMID 27459707 Get It

Telomeres cap chromosome ends, protecting them from degradation, double‐strand breaks, and end‐to‐end fusions. Telomeres are maintained by telomerase, a reverse transcriptase encoded by TERT, and an RNA template encoded by TERC. Loci in the TERT and adjoining CLPTM1L region are associated with risk of multiple cancers. We therefore investigated associations between variants in 22 telomere structure and maintenance gene regions and colorectal, breast, prostate, ovarian, and lung cancer risk. We performed subset‐based meta‐analyses of 204,993 directly‐measured and imputed SNPs among 61,851 cancer cases and 74,457 controls of European descent. Independent associations for SNP minor alleles were identified using sequential conditional analysis (with gene‐level p value cutoffs ≤3.08 × 10−5). Of the thirteen independent SNPs observed to be associated with cancer risk, novel findings were observed for seven loci. Across the DCLRE1B region, rs974494 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Across the TERC region, rs75316749 was positively associated with colorectal, breast, ovarian, and lung cancers. Across the DCLRE1B region, rs974404 and rs12144215 were inversely associated with prostate and lung cancers, and colorectal, breast, and prostate cancers, respectively. Near POT1, rs116895242 was inversely associated with colorectal, ovarian, and lung cancers, and RTEL1 rs34978822 was inversely associated with prostate and lung cancers. The complex association patterns in telomere‐related genes across cancer types may provide insight into mechanisms through which telomere dysfunction in different tissues influences cancer risk.
Abstract 5221: Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors
Zaidi, Syed Hassan Ejaz , Grasso, Catie, Mu, Jasmine, Giannakis, Marios , Connolly, Charles M. , Brenner, Hermann , Chang‐Claude, Jenny , Du, Mengmeng , Ferretti, Vincent , French, Amy J. , Fuchs, Charles S. , Gallinger, Steven , Garraway, Levi A. , Gsur, Andrea , Harrison, Tabitha A. , Hoffmeister, Michael , Huyghe, Jeroen R. , Lemire, Mathieu , McPherson, John D. , Timms, Lee E., Wheeler, David A. , Zubair, Niha, Thibodeau, Stephen N. , Peters, Ulrike , Shinbrot, Eve , Borozan, Ivan , Campbell, Peter T. , Chan, Andrew T. , Gunter, Marc J. , Hsu, Li , Huang, Wen‐Yi , Mardis, Elaine R. , Newcomb, Polly A. , Stein, Lincoln , Sun, Wei , Trinh, Quang M. , Yung, Christina K. , Ogino, Shuji , Hudson, Thomas J , Hoffmeister, Michael , Harrison, Tabitha A , Brenner, Hermann

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 5221-5221

10.1158/1538-7445.am2016-5221 Get It

Abstract The completion of The Cancer Genome Atlas (TCGA) project for colorectal cancer (CRC) has enabled a new, focused phase of sequencing tumor samples for which genome-wide genetic, epidemiological, clinical and lifestyle data have been collected. By combining somatic mutational profiles with these aforementioned data, we may identify and report effective prevention and treatment approaches for a broader population of individuals. The advent of targeted deep sequencing approaches using DNA obtained from formalin fixed paraffin embedded tissues has made possible the genetic characterization of the large numbers of patients needed to make such an effort relevant. As a first step, we describe a custom gene panel designed from large-scale studies for targeted deep sequencing, and its application to over 4,200 CR tumors, collected by the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). This study is designed to identify recurrent somatic mutations and copy number alterations (CNAs) for association testing with germline genetic and lifestyle and environmental risk factors for CRC, and thereby identify relevant approaches to impact cancer prevention. The targeted CRC panel includes 205 genes. Genes were primarily selected as significantly mutated genes identified from the Nurses’ Health Study and Health Professional's Follow-up Study (n = 700), and TCGA (n = 525). We also included 15 genes associated with high penetrance germline mutations and augmented the list to include genes in pathways of somatically altered genes, identified by literature review, from public databases and known to be associated with loss of heterozygosity. For these 205 genes, amplification primers were designed to include all coding regions of transcripts that are listed in the UCSC Genome Browser. For regions with CNAs, the TCGA dataset was analyzed to include regions with greater than or equal to 2 copy focal gains or losses that were found in more than 4 or 3 tumors, respectively. Candidate genes in regions with significant CNAs from the TCGA CRC publication (Nature 2012) were also included. For CNAs, 6 to 12 amplicons were designed for each of the 56 selected regions (32 gains and 24 losses). Additional target regions include: 1) 25 microsatellite loci previously used to identify defective DNA mismatch repair and 212 homoploymer repeats. These include microsatellite loci recommended by the NCI Consensus Panel for identifying MSI; 2) amelogenin (for gender); and 3) Fusobacterium to detect a putative CRC-associated pathogen in tumor biopsies. At the AACR annual meeting, we expect to present results for deep sequencing (∼1,000X) of the first 1,000 CR tumors, including any preliminarily identified pathways and subtypes that may provide the basis for association testing with germline genetic and lifestyle and environmental risk factors needed for inferring better approaches to prevention and treatment of CRC. Citation Format: Syed H. Zaidi, Catie Grasso, Jasmine Mu, Eve Shinbrot, Marios Giannakis, Charles Connolly, Ivan Borozan, Hermann Brenner, Peter Campbell, Andrew Chan, Jenny Chang-Claude, Mengmeng Du, Vincent Ferretti, Amy French, Charles Fuchs, Steven Gallinger, Levi Garraway, Andrea Gsur, Marc Gunter, Tabitha Harrison, Michael Hoffmeister, Li Hsu, Wen-Yi Huang, Jeroen Huyghe, Mathieu Lemire, Elaine Mardis, John McPherson, Polly Newcomb, Lincoln Stein, Wei Sun, Lee Timms, Quang Trinh, David Wheeler, Christina Yung, Niha Zubair, Shuji Ogino, Stephen Thibodeau, Ulrike Peters, Thomas Hudson. Linking the molecular profile of colorectal tumors to germline genetic and environmental risk factors. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 5221.
Abstract 1762: Body mass index shows etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin
Breitenstein, Matthew K. , O’Byrne, Megan M., Thompson, Carrie A. , Macon, William R. , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Feldman, Andrew L. , Slager, Susan L. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

Cancer Research | July 26, 2016 | Volume: 76 | Issue: 14_Supplement | Pages: 1762-1762

10.1158/1538-7445.am2016-1762 Get It

Abstract Background. DLBCL is the most common non-Hodgkin lymphoma (NHL) subtype in western countries and is known to be clinically heterogeneous. Gene expression profiling has identified two major, biologically distinctive DLBCL subtypes on the basis of their cell-of-origin (COO): the germinal center B-cell (GCB) - characterized by BCL2 rearrangement and C-REL amplification, and activated B-cell (ABC) - characterized by constitutive activation of the NF-kB pathway. Recently, the InterLymph Subtypes Project identified medical history, lifestyle, and family history risk factors for DLBCL using a large pooled analysis of case-control studies. In this study we evaluated these same risk factors for etiologic heterogeneity as defined by DLBCL COO. Methods. For this analysis we used a clinic-based study of newly diagnosed NHL cases and frequency matched controls, enrolled from 2002-2012, with 474 DLBCL cases and 2203 controls. COO was determined clinically using the Hans algorithm, which is based on immunohistochemistry markers using formalin-fixed, paraffin-embedded tumor tissue. Amongst DLBCL cases 107 were ABC, 207 were GCB, and 160 were missing subtype (tissue unavailable). Risk factor data, including body mass index (BMI), smoking, alcohol use, any allergy, asthma, blood transfusion, diabetes, rheumatoid arthritis, sun exposure, lived on a farm and family history of hematologic malignancy, were collected from self-administered questionnaires. Polytomous logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals for ABC and GCB subtypes, adjusted for age and sex. Results. The mean age of cases was 60.4 years with 53% male; the mean age of controls was 61.6 years and 53% male. We identified a strong positive association for BMI with risk of ABC but not GBC DLBCL (p-heterogeneity 0.025). Compared to BMI 18.5-24.9 kg/m2, those with a BMI of 25.0-29.9 (OR = 1.65; 0.93-2.93) or 30+ (OR = 2.61; 1.48-4.62) were at increased risk of ABC DLBCL. There was no association for a BMI of 25.0-29.9 (OR = 0.91; 0.63-1.31) or 30+ (OR = 1.21; 0.83-1.76) with GCB DLBCL. There was no evidence of significant heterogeneity between ABC and GCB DLBCL for the other risk factors that we evaluated. Further adjustment of the BMI association for educational level, smoking, and alcohol only slightly attenuated these findings. Conclusions. We observed a strong positive association of BMI with ABC but not GCB DLBCL. In contrast, other evaluated risk factors showed no heterogeneity by COO. While BMI has not been clearly associated with NHL overall, there has been evidence for an association with DLBCL. The etiologic heterogeneity we observed for ABC DLBCL is notable as BMI is also a strong risk factor for multiple myeloma, another post-germinal center B-cell malignancy. While requiring replication, our findings suggest BMI may influence B-cell neoplasia through effect on post-germinal center pathways. Citation Format: Matthew K. Breitenstein, Megan M. O’Byrne, Andrew L. Feldman, Carrie A. Thompson, William R. Macon, Grzegorz S. Nowakowski, Stephen M. Ansell, Susan L. Slager, Thomas M. Habermann, James R. Cerhan. Body mass index shows etiologic heterogeneity for risk of diffuse large B-cell lymphoma (DLBCL) subtype defined by cell-of-origin. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 1762.